Overview

Paul J. Jaskot is a corporate services attorney in Holland & Knight's Philadelphia office, where he focuses on mergers and acquisitions, securities, corporate governance, general corporate and financing matters. He counsels a wide range of clients, from early-stage companies to well-established, publicly traded enterprises, to professional services firms.

Mr. Jaskot works closely with clients' senior management and other personnel in industries such as banking and financial services, healthcare and life sciences, insurance, media, consumer products, professional services, information technology, telecommunications, transportation, chemicals and energy.

Prior to joining Holland & Knight, Mr. Jaskot served as the lead executive committee member and chair of the U.S. corporate and securities group for a large international law firm.

Experience

  • Represented Enterprise Financial Services Group in two key strategic transactions:

    • Enterprise's acquisition of Jefferson County Bancshares Inc. and its wholly owned subsidiary, Eagle Bank and Trust Company of Missouri
    • Enterprise's $50 million registered debt offering of 4.75 percent fixed-to-floating rate subordinated notes due Nov. 1, 2026
  • Represented Catalyst Funds, an alternative-focused mutual fund company, in the acquisition of Huntington Asset Advisors, the advisor to a family of mutual funds, variable annuity funds and exchange-traded funds (ETFs)
  • Represented Capital Funding Bancorp Inc. in its $35 million private placement of 7.50 percent fixed-to-floating rate subordinated notes due 2027
  • Represented Alpha Strategic in a "revenue share" investment in a New York-based alternative asset manager engaged in relative value trading and fundamental credit investing, with a focus on residential assets and mortgage-backed securities
  • Serves as corporate counsel to the developer of a wealth management application and integrated business development solution for financial advisors, wealth managers and money managers
  • Closed multiple series of preferred stock and convertible debt financings on behalf of a cloud-based online organizer
  • Represented Morgan Stanley in a complex sale of its personal trust business that was originally structured as bulk sale but subsequently changed to a transfer of individual accounts
  • Acted as outside general counsel for National Penn Bancshares Inc. (now BB&T) for 10-plus years, over the course of which he assisted National Penn with multiple acquisitions and divestitures, regulatory and compliance issues, and corporate governance matters, including:

    • A $150 million private equity investment by Warburg Pincus in National Penn
    • National Penn's acquisitions of Nittany Financial Corp., KNBT Bancorp Inc. and TF Financial for cash and stock
    • National Penn's acquisition and subsequent divestiture of Christiana Bank and Trust Co.
  • Represented Capital One in the sale of its municipal trust business to an affiliate of M&T Bank
  • Represented Billing Services Group Ltd. in the sale of its European wireless business to Syniverse Technologies Inc. for $290 million in cash and a related $112.5 million refinancing of its U.S. operations
  • Represented Bryn Mawr Bank Corp., parent company of The Bryn Mawr Trust Company, in connection with its acquisition of Royal Bancshares of Pennsylvania Inc., the parent company of Royal Bank America
  • Represented a leading revenue cycle management company in its sale transaction to a private equity sponsor

  • Served as corporate counsel and trusted advisor to multiple specialty pharmaceutical companies, advising on corporate and securities matters, strategic transactions and other significant company initiatives, including:

    • Represented Select Medical Corp., a Mechanicsburg, Pa., operator of long-term acute care hospitals (LTACHs) and inpatient rehabilitation hospitals, in acquisition and joint venture transactions across the country
    • Represented Select Medical in multiple home health, LTACH, rehabilitation hospital, occupational medicine and physical therapy acquisitions in M&A matters
  • Worked on several hospital joint venture transactions in which Select Medical's joint venture counterparty in each case is a leading academic medical center in the region, as well as multiple physician group joint ventures
  • Represented Columbus Radiology, a leading subspecialty radiology group serving 45 total sites, 15 hospitals and eight health systems, in its sale to Radiology Partners
  • Served as M&A counsel to Calixa Therapeutics Inc., a biopharmaceutical company focused on the development of novel antibiotics, in connection with its sale to Calixa Pharmaceuticals Inc. for consideration of up to approximately $400 million
  • Represented Talecris Biotherapeutics, a global biotherapeutic and biotechnology company, in the acquisition of 58 plasma collection centers, as well as in several follow-on acquisitions and plasma supply agreements
  • Represented Abington Health in its merger with Thomas Jefferson University's Jefferson Health; both Jefferson and Abington are among the Philadelphia region's leading nonprofit health systems
  • Represented one of the largest U.S. independent home infusion providers and its founder/CEO in two successive sale transactions to two healthcare-focused private equity sponsors
  • Represented Passaic Beth Israel Hospital, a New Jersey nonprofit community hospital, in a complex series of transactions under which the hospital purchased the facility of a competing hospital, relocated its operations to the new facility and sold its pre-existing property in a condemnation action to a state agency for development as public school facilities
  • Represented Tenet Healthcare Corp. in the sale of Roxborough Memorial Hospital and Warminster Hospital to Solis Healthcare
  • Represented a leading global medical device company in connection with its preferred stock investment in a biotechnology company focused on the treatment, repair and replacement of human tissue
  • Represented a leading operator of specialty hospitals in the U.S. in connection with its acquisition of two acute rehabilitation hospitals

  • Representing a leading professional services firm in acquisition of a competing professional services firm.
  • Represented Haddon House Food Products, a national distributor and merchandiser of natural, organic and gourmet ethnic products, in connection with its sale to United Natural Foods Inc. (UNFI), a leading distributor of natural and organic foods, for approximately $217.5 million
  • Represented a leading consumer products (crafts) company in its sale to a U.S.-based international private equity fund
  • Represented Northill Capital in its acquisition of a majority stake in U.S. growth equity manager Riverbridge Partners LLC
  • Advised a publicly held specialty and casualty insurance holding company on corporate governance, U.S. Securities and Exchange Commission (SEC) reporting and other matters in its merger of equals transaction
  • Represented a Philadelphia-based, publicly traded insurer in its acquisition of a specialty insurance brokerage
  • Represented an international provider of mobile data solutions in its acquisition of a U.S. provider of specialized mobile workforce solutions
  • Represented Australia's leading integrated energy, greenhouse and sustainable solutions provider in the sale of its U.S. subsidiary to a London-based, publicly traded renewable energy company
  • Represented a publicly held U.S. newspaper publishing company in its acquisition of a network of regional employment websites

  • Advised the world's largest shipbroker, Clarksons PLC, on a lead investment in CargoMetrics, a U.S. technology-driven investment company
  • Represented Essex Woodlands Health Ventures, one of the oldest and most respected healthcare growth equity and venture capital firms in the world, in several strategic investment transactions, including:

    • the Series E preferred stock financing of Prolacta Bioscience Inc., a California-based company that develops and manufactures human milk-based nutritional products for premature infants and other similar uses
    • the Series B preferred stock financing of Encore Dermatology Inc., a leader in developing and commercializing novel, prescription products for improving skin health
  • Represented Nuron Biotech, a specialty biologics and vaccines company, in an $80 million financing transaction with HealthCare Royalty Partners II LP, a global healthcare investment firm
  • Advised Wasena Capital Management in connection with its early stage investment in ByoPlanet International, the industry leader in advanced induction-charged mechanical delivery systems
  • Advised a newly formed investment firm – founded by three pharmaceutical industry veterans and specializing in growth investment and turnaround opportunities in the pharmaceutical and biologics sectors – on corporate, securities and related formation issues
  • Represented one of the nation's largest networks of integrated, community-based oncology practices in the formation of a proton therapy joint venture
  • Represented one of the fastest-growing, cold-pressed juice, smoothie and raw food companies in the Philadelphia region in an angel round equity financing Represented a leading revenue cycle management company in its recent sale transaction to a private equity sponsor

Credentials

Education
  • Temple University, Beasley School of Law, J.D., magna cum laude
  • Yale University, B.A.
Bar Admissions/Licenses
  • New Jersey
  • New York
  • Pennsylvania
Memberships
  • Tech Impact, Board of Directors, Chair
Honors & Awards
  • Best Lawyers in America guide, Securities/Capital Markets Law, 2017-2019 
  • Chambers USA – America's Leading Business Lawyers guide, Corporate/M&A & Private Equity, 2016-2019
  • Client Service All-Star, The BTI Consulting Group Inc., 2015

News